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The protein sequence of MAP kinase-activated protein kinase 2 (MAPKAP kinase 2) deduced from mouse cDNA sequence reveals structural 
features of the enzyme, which could be of importance for its function: a proline-rich SH3-binding domain N-terminal to the catalytic region, a 
MAP kinase phosphorylation site and a bipartite nuclear targeting sequence located C-terminal to the catalytic region. The catalytic domain itself 
has the strongest homology to calcium/calmodulin-dependent protein kinase II. Northern blot analysis demonstrates a 3.5 kb MAPKAP kinase 
2 transcript which is ubiquitously expressed and, hence, co-expressed with the mRNA of the recently identified substrate Hsp25 in all tissues 
analysed. However, the functional consequences of the nuclear targeting sequence present in MAPKAP kinase 2 suggest he existence of further 
substrates for the enzyme in the nucleus. 
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1. INTRODUCTION 
Protein phosphorylation represents a key mechanism 
of transduction in mitogenic signalling, e.g. by activat- 
ing MAP kinase via the MAP kinase cascade. MAP 
kinase-activated protein kinase 2 (MAPKAP kinase 2) 
has been described as an enzyme which is activated by 
phosphorylation via MAP kinases [l]. This property of 
MAPKAP kinase 2 is shared with the 90 kDa ribosomal 
S6 kinases (RSKs; members of the RSK family are also 
referred as S6 kinase I and II, ISPKl or MAPKAP 
kinase 1) which are also phosphorylated and activated 
by MAP kinase as a result of mitogenic stimulation [2]. 
The substrate used for initial purification of MAPKAP 
kinase 2 was a peptide derived from the N-terminal part 
of glycogen synthase [l]. The small heat shock proteins 
(sHsps) have been identified as further substrates. Both, 
the small heat shock protein from mouse, Hsp25, and 
from human, Hsp27, have been demonstrated to be 
phosphorylated very efficiently by MAPKAP kinase 2 
in vitro [3] at the same sites which are phosphorylated 
in vivo [4,5]. It is not clear whether the sHsps are the 
only physiological substrates of this enzyme and 
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whether phosphorylation of sHsps is the main process 
relevant for the biological function of this enzyme. 
In this paper we describe cloning and sequencing of 
mouse MAPKAP kinase 2 cDNA resulting in identifi- 
cation of primary structure motifs which may prove to 
be of important influence on regulation of function and 
subcellular localisation of MAPKAP kinase 2. 
2. EXPERIMENTAL 
2.1. Polymerase chain reaction 
Degenerate oligonucleotide 5’-GA(TC)GTNAA(AG)CCNGA- 
(AG)AA(TC)(TC)T-3’ and 5’TCCANGG(AG)TG(AG)TTCAT(AGb 
AA-3’ derived from the sequence of the tryptic peptides of domains 
VIb (DVKPENL) and XI (FMNHPWI) [ 1.61 were used as primers in 
a PCR reaction with mouse cDNA as template. The fragment ampli- 
fied was cloned into pUC18 (Sure Clone Ligation Kit, Pharmacia). 
DNA sequencing was carried out in both directions using double- 
strand plasmid and Sequenase 2.0 (US Biochemical Corp.). The de- 
duced amino acid sequence of the fragment was verified to be a part 
of the MAPKAP kinase 2 sequence by showing identity to the peptides 
known from rabbit MAPKAP kinase 2 [l]. A hybridisation probe for 
screening of the cDNA library and northern hybridisation was gener- 
ated from the cloned PCR fragments by random priming and labelling 
with [cc-“P]ATP (3000 Ci/ mmol) (Megaprime labelling kit, Amer- 
sham). 
2.2. cDNA-screening and rapid amp&cation of cDNA encLF (RACE) 
A mouse lung cDNA library in gtl0 was screened using the PCR 
fragment as probe. Four different clones were identified and se- 
quenced as described above. Rapid amplification of cDNA ends [7j 
was carried out using the Y-AmpliFINDER RACE Kit (Clontech, 
Palo Alto, CA) and the primers Pl (5’-ATGTGTGGGCACTGGG- 
AGG-3’) and P2 (5’~CGAAGATCCGCAGCACC-3’) complemen- 
tary to the cloned 5’ region of the cDNA. 
2.3. Northern blot experiments 
A mouse Multi Tissue Northern Blot containing 2 g of electro- 
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Fig. 1. cDNA sequence and deduced protein structure of MAPKAP kinase 2. The stop codon and polyadenylation signal are underlined. The protein 
sequence of MAPKAP kinase 2 deduced from the open reading frame is shown in one letter code. The proline-rich SH3-binding domain, the MAP 
kinase phosphorylation site and the bipartite nuclear targeting sequence are underlined, the consensus equence for the SH3-binding domain and 
the MAP kinase recognition motif are given in italics and aligned to the sequence. The bipartite nuclear targeting sequence is indicated by NTSl 
and NTS2. The protein kinase catalytic domain sequence motifs (I-XI) are marked and the highly conserved amino acid residues of these motifs 
are underlined. 
phoretically separated poly(A)’ mRNA from each tissue was obtained 
from Clontech (Palo Alto, CA). Probes used were the MAPKAP 
kinase 2 PCR fragment, an about 600 bp Hind111 cDNA fragment of 
Hsp25 [8] and a 2 kb probe for human @&in. Hybridisation was 
carried out in 5 x SSPE, 10 x Denhardt’s reagent, 2% SDS, 50 &ml 
fragmented salmon sperm DNA, 50% formamide at 42°C overnight. 
Filters were washed three times for 10 min in 2 x SSC, 0.05% SDS at 
room temperature, and twice for 15 min in 2 x SSC, 0.1% SDS at 
50°C. Northern blot analysis and quantification was performed using 
the Bio Imaging analyser BAS 2000 (Fuji). 
3. RESULTS 
3.1. cDNA and deduced protein sequence of MAPKAP 
kinase 2 
Two degenerate oligonucleotides were derived from 
the sequence of tryptic peptides of the catalytic domain 
motifs VIb and XI of rabbit MAPKAP kinase 2 [l]. The 
oligonucleotides were used to amplify a 418 bp mouse 
cDNA fragment of MAPKAP kinase 2, which was fur- 
ther taken as probe for screening of a mouse lung 
cDNA library in AgtlO. Four different types of overlap- 
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ping cDNA clones were isolated and analysed. All 
clones obtained lack the part corresponding to the ex- 
treme 5’-end of the MAPKAP kinase 2-mRNA and the 
translation start site. Further screening of the cDNA 
library and RACE did not provide cDNA clones which 
code for the translation start of MAPKAP kinase 2. 
This is probably a result of the extremly GC-rich region 
at the 5’-end of the mRNA sequence, which may pro- 
duce stable secondary mRNA structure and thereby 
inhibits full-length first strand cDNA synthesis 171. Sim- 
ilar problems caused by 5’ GC-rich regions have been 
described in cloning for the MAP kinase erk-I cDNA 
[9].The cDNA sequence and translated protein se- 
quence of MAPKAP kinase 2 is shown in Fig. 1. The 
cDNA sequence represents an open reading frame of 
1149 bp, coding for a polypeptide of 383 amino acids. 
It contains a stop codon and a polyadenylation signal 
AATATA 21 bp upstream of the poly(A) tail in the 3’ 
non-translated region. The deduced protein sequence of 
MAPKAP kinase 2 shows two overlapping proline-rich 
SHZbinding domains with the sequence IpFgAPPPP- 
ApAaFg N-terminal to the catalytic domain of 
the kinase. At least one of these overlapping motifs 
perfectly matches the SH3-binding consensus equence 
PXXPPPyl;yP (w represents a hydrophobic amino acid 
residue) [lo]. The catalytic domain of MAPKAP kinase 
2 is characterised by the various conserved motifs (I-XI, 
cf. [6]) as well as by the occurrence of the sequences of 
the tryptic peptides obtained form rabbit MAPKAP 
kinase 2 [l]. The MAP kinase phosphorylation site in 
rabbit MAPKAP kinase 2 has already been identified 
[I]. In the deduced amino acid sequence of mouse 
MAPKAP kinase 2 this site is located C-terminal to the 
catalytic domain within the sequence motif PQT*P, 
which is in agreement with the MAP kinase recognition 
motif PXS/TP [I l]. This finding is in contrast to the 
position of the phosphorylation sites of other protein 
kinases as ISPKl (RSK, MAPKAP kinase 1) [12], 
CAMP-dependent protein kinase [13], MAP kinase [14] 
and p34cdc2 kinase [15], which are located within the 
catalytic domain N-terminal to the motif VIII [6]. Inter- 
estingly, the phosphorylation site of MAPKAP kinase 
2 is followed by an ideal bipartite nuclear targeting 
signal KK(X),,KRRKK, which has been described to 
be sufficient for nuclear l~alisation of a variety of pro- 
teins 1161. 
3.2. Homology to other protein kinases 
The primary structure of the catalytic domain of 
MAPKAP kinase 2 was compared to the other protein 
kinases contained in the Protein Kinase Catalytic Do- 
main Database (cf. 161) using the method of Needleman 
and Wunsch [17]. The sequence of highest homology is 
the a a subunit of rat calcium/calmodulin-dependent 
protein kinase II (score 50.8) followed by myosin light 
chain kinase from chicken smooth muscle (score 30-Q 
the C-terminal catalytic domain of mouse RSK kinase 
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Fig. 2. Comparison of MAPKAP kinase 2 catalytic domain with 
catalytic domains of similar proteins kinases. MK2 = mouse 
MAPKAP kinase 2; CAMII_A = cc subunit of rat calcium/calmod- 
ulin-dependent protein kinase II; MLCK_M = myosin light chain ki- 
nase from chicken smooth muscle; RSKl_C = C-terminal catalytic 
domain of mouse RSK kinase and PSK_Hl = putative protein-serine 
kinase PSK Hl from HeLa cells. Identities and strong similarities 
(Y=F,Q=E,V=I,M=L,R=K,D=E,S=T,N=E,H=Q, 
N = H) to MAPKAP kinase 2 are shown by uppercase letters. The 
su~omains I to XI (cf. [S]) are indicated and the conserved amino acid 
residues of these domains are marked with an asterisk. 
(score 27.8) and the putative protein-serine kinase cells 
PSK HI from HeLa (score 27.8). The alignment of the 
catalytic domains of these kinases to MAPKAP kinase 
2 is shown in Fig. 2. Interestingly, the homologous ki- 
nases are exclusively located in a cluster of the phylo- 
genetic kinase tree known to contain calcium/calmod- 
ulin-dependent protein kinases, However, until now no 
c~ci~calmodulin dependence of the MAPKAP ki- 
nase 2 [l] and other members of this cluster as RSK Cl, 
RSK C2 and PSK HI has been observed (61. 
3.3. Co-expression of MA PKA P kirzase 2 and Hsp25 
Northern blot experiments revealed an about 3.5 kb 
mRNA for mouse MAPKAP kinase 2 (Fig. 3). The 
large size of the MAPKAP kinase 2-mRNA cannot be 
explained by the coding and 3’ non-translated region 
analysed and is probably the result of the size of the 
5’ non-translated region. In all mouse tissues under in- 
vestigation expression of MAPKAP kinase 2 could be 
detected. Using specific DNA probes we have also mon- 
itored expression of the MAPKAP kinase 2 substrate 
145 
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Hsp25 
MAPKAP Kinwe 
Actin 
Fig. 3. Northern blot analysis of expression of MAPKAP kinase 2 and 
Hsp25. Expression of Hsp25-mRNA (a), MAPKAP kinase 2-mRNA 
(b) and /3-actin-mRNA (c) in different mouse tissues. 
Hsp25 and as a control the expression of /3-actin. The 
relative amount of specific MAPKAP kinase 2-mRNA 
and Hsp25-mRNA compared to the /?-actin signal was 
quantitatively analysed by phospho-imaging and is 
shown in Table I. Interestingly, the lowest expression of 
both MAPKAP kinase 2-mRNA and Hsp25-mRNA 
compared to @-actin-mRNA is detected in liver, kidney 
and brain. The highest relative expression of enzyme 
and substrate-mRNA is calculated for spleen, caused by 
relatively low abundant j?-actin-mRNA. A high relative 
expression of MAPKAP kinase 2- and Hsp25-mRNA 
is also detected in lung and testis, followed by heart and 
muscle. 
4. DISCUSSION 
To our knowledge, MAPKAP kinase 2 is the first 
protein kinase which contains a proline-rich SH3 do- 
main-binding sequence motif. This motif has been iden- 
tified in different proteins, e.g. formins, muscarinic ace- 
tylcholine receptor [lo] and Drosophila SOS [ 181. The src 
homology 3 (SH3) domain binding to the proline-rich 
sequence is present in a variety of molecules involved in 
signal transduction, as the family of SH3-SH2-adaptors 
including WV [19] and Drosophila drk [20], the tyrosine 
kinase oncogenes c-ubl and c-src [21] as well as phos- 
pholipase Cy, phosphatidyl inositol-3-kinase and 
GTPase activating protein GAP (for review see [22]). 
Furthermore, SH3 domains are also found in proteins 
involved in cytoskeletal architecture as spectrin and 
actin-binding proteins (see [22]). The presence of a pro- 
line-rich SH3 domain-binding motif in MAPKAP ki- 
nase 2, which is located at a relatively late position in 
the mitogenic signal transduction pathway, opens up 
new possibilities in feedback control of signalling or in 
further signal transduction influencing cytoskeletal or- 
ganisation. The identification and characterisation of 
SH3 domain containing target proteins which bind to 
MAPKAP kinase 2 will probably provide better under- 
standing of these processes. 
The MAPKAP kinase 2-mRNA is demonstrated to 
be ubiquitously expressed in the various mouse tissues 
used for the Northern blot analysis. Since Hsp25- 
mRNA is also constitutively expressed in these tissues, 
a co-expression of MAPKAP kinase 2 and the substrate 
Hsp25 can be demonstrated (cf. Table I). However, this 
result does not exclude that both proteins are localised 
in different cellular compartments. The ideal bipartite 
NTS motif in the C-terminal region of MAPKAP kinase 
2 raises the question of functional significance of this 
motif. Taking into account the ideal fit of the MAPKAP 
kinase 2 sequence motif with the NTS consensus se- 
quence and that degenerated NTS motifs are present 
only in 4.2% of the non-nuclear protein sequences con- 
tained in the SwissProt Database [16], it is most likely 
that this motif is responsible for nuclear localisation of 
MAPKAP kinase 2. Furthermore, the close proximity 
of the MAP kinase phosphorylation site, threonine-317, 
to the bipartite NTS (lysine-356 to lysine-372) raise the 
possibility of modulation of nuclear targeting activity of 
MAPKAP kinase 2 by phosphorylation [23]. As demon- 
strated for the simian virus 40 large T-antigen, nuclear 
transport kinetics is increased after phosphorylation at 
sequences flanking the NTS [24]. Accordingly, it could 
be speculated that activation of MAPKAP kinase 2 via 
phosphorylation by MAP kinase also modulates its cel- 
lular localisation by increasing translocation to the nu- 
Hsp25 
MK2 
Table I 
Relative level of expression of MAPKAP kinase 2 (MK2) and Hsp25 mRNA in different mouse tissues 
Heart Brain Spleen Lung Liver Muscle Kidney Testis 
3.1 0.4 5.5 5.2 0.3 3.1 0.5 5.2 
0.5 0.15 3.6 1.0 0.2 0.8 0.2 1.0 
Hybridisation signal was quantified by phospho-imaging and normalised by the signal obtained with the /I-actin probe. 
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cleus. This hypothesis would be parallel to the observa- 
tion that a fraction of MAP kinases and RSKs enters 
the nucleus after phosphorylation [25], indicating a gen- 
eral mechanism for transduction of mitogenic signals to 
the nucleus. 
In any case, nuclear localisation of MAPKAP kinase 
2 would favour also nuclear substrates, e.g. transcrip- 
tion factors which are phosphorylated in response to 
mitogenic signals. In contrast, the substrates identified 
so far, glycogen synthase [l] and the small heat shock 
proteins [3] are localised in the cytosol. A translocation 
of the sHsps to the nuclear region has been described 
as a result of heat shock [26] but not as the result of 
mitogenic stimulation. Furthermore, after heat shock 
no significant differences in the degree of phosphoryla- 
tion of sHsps in the cytosol and in the nuclear fraction 
could be demonstrated [27,28]. These data could be ex- 
plained by a cytosolic activity of MAPKAP kinase 2. 
The analysis of the intracellular localisation of 
MAPKAP kinase 2 in dependence on its degree of phos- 
phorylation should provide further inside into these 
questions. 
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